Company Overview and News

0
Energy storage must be at heart of our future grid, Alan Finkel says

2018-07-06 theage.com.au
Chief Scientist Alan Finkel says Australia is taking a world-leading position in energy storage – beyond just batteries – and must put the technology at the centre of its own energy transition.
GNX

0
Energy storage must be at heart of our future grid, Alan Finkel says

2018-07-06 smh.com.au
Chief Scientist Alan Finkel says Australia is taking a world-leading position in energy storage – beyond just batteries – and must put the technology at the centre of its own energy transition.
GNX

0
Genex Power Ltd set to finalise 'some major milestones' in next six months

2018-06-29 proactiveinvestors.com.au
Genex Power Ltd (ASX:GNX) executive director Simon Kidston tells Proactive Investors all the latest regarding the development of The Genex Kidston Renewable Energy Hub in north Queensland. The renewable energy generation and storage company is in the midst of developing the project in three stages.
GNX

0
Coal-linked government fund pumps $500m into QLD renewable project

2018-06-20 theage.com.au
Genex Power’s Queensland-based Kidston pumped hydro storage and solar project has received more than $500 million from a government infrastructure fund that has previously drawn flak as a facility to prop up coal projects.
GNX

0
Coal-linked government fund pumps $500m into QLD renewable project

2018-06-20 smh.com.au
Genex Power’s Queensland-based Kidston pumped hydro storage and solar project has received more than $500 million from a government infrastructure fund that has previously drawn flak as a facility to prop up coal projects.
GNX

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to ASX:GNX / GENEX POWER LIMITED on message board site Silicon Investor.

MGNX -- MacroGenics Zogenix - ZGNX
VGNX -- Variagenics, Inc. VGNX: Variagenics, Inc.
CGNX, NIS, BRCD, AHP, SCH, LU, CSCO, TDY Articles Lignex--(LGNX-OTC)
Genomics One Corporation (gnx) Cognex (CGNX-OTC) Did you know...